Skip to main content

Table 1 Patients characteristics

From: The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas

 

AA

n = 23

GBM

n = 116

Age in years

 Median

50

65

 Range

25–74

26–81

 Age (> 65, <= 65)

6, 17

63, 53

Gender (male/female)

13, 10 (1.30:1.00)

69, 47 (1.49:1.00)

Extent of resection

 GTR

14 (61%)

89 (77%)

 STR

5 (22%)

25 (22%)

 Biopsy only

4 (17%)

1 (1%)

 N.d.

0

1 (1%)

KPS (> 70, <= 70, n.d.)

15 (65%), 6 (26%), 2 (9%)

42 (36%), 73 (63%), 0

IDH +, IDH -

13 (57%), 10 (43%)

6 (5%), 110 (95%)

MGMT+, MGMT-, MGMT n.d.

20 (87%), 3 (13%), 0

43 (37%), 71 (61%), 2 (2%)

IDH+ & MGMT+

12 (52%)

6 (26%)

IDH- & MGMT-

2 (7%)

71 (61%)

IDH+ & MGMT-

1 (4%)

0

IDH- & MGMT+

8 (35%)

37 (32%)

EGFR+, EGFR -, EGFR n.d.

5 (50%), 5 (50%), 0

53 (46%), 61 (54%), 3 (2%)

  1. AA anaplastic astrocytoma, GBM glioblastoma, GTR gross total resection, STR subtotal resection, n.d. not determined, KPS Karnofsky Performance Scale, IDH+ IDH1 or IDH2 mutation, IDH- no IDH1 or IDH2 mutation, MGMT+ promoter methylation, MGMT- no promoter methylation, EGFR+ amplification, EGFR- no amplification